Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    29-December-2000      
Issue 260 Next Update - 14:00 UTC 08:00 EST    30-December-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya Today In Vidyyasm

Vidyya Medical News Service For 29-December-2000:

The following stories appear in full on today's Vidyya Medical News Service Web site.

Smoking greatly increases the risk of developing a particular type of skin cancer, researchers from the Leiden University Medical Center in the Netherlands, have found. Squamous Cell Carcinoma is already one of the more common skin cancers, normally developing later in life.

For more information: Smoking Can Triple Skin Cancer Risk

The R.W. Johnson Pharmaceutical Research Institute (PRI), a member of the Johnson & Johnson family of companies, submitted its New Drug Application (NDA) for the Ortho Evra(TM) (norelgestromin/ethinyl estradiol) transdermal system, a seven-day contraceptive patch, to the U.S. Food and Drug Administration. The FDA's standard review period for an NDA is 12 months. If approved, Ortho Evra would be the world's first prescription transdermal contraceptive.

For more information: Transdermal Method Of Contraception Submitted For FDA Approval

A new brain imaging study from the Institute of Psychiatry shows for the first time that the thalamus, the brain's main sensory filter or 'hub', is smaller than normal from the earliest stages of schizophrenia. The findings, published in the American Journal of Psychiatry in January, may explain why people with schizophrenia experience confusion during their illness.

For more information: New MRI Technique Shows Thalamus Is Smaller Than Normal From The Earliest Stages Of Schizophrenia

Novartis has announced that the US Food and Drug Administration (FDA) has granted marketing approval for Starlix® (nateglinide), the first in a new class of oral antidiabetic drugs that restores early insulin secretion, a fundamental defect in type 2 diabetes. It is indicated for use as both monotherapy and in combination with metformin, another oral antidiabetic medication, in patients whose blood glucose (sugar) is not controlled by diet and exercise. In the United States, more than 13 million people have type 2 diabetes and the incidence is expected to increase.

For more information: US FDA approves Novartis' Starlix

Study results published in the current issue ofThe Lancet (vol 356, issue 9248) show that Exelon® (rivastigmine) alleviates behavioral disturbances in patients with dementia with Lewy bodies (DLB). DLB (also referred to as the Lewy body variant of Alzheimer's disease) is the second most common form of dementia1 and is characterized by severe behavioral disturbances.

For more information: Rivastigmine Alleviates Behavioral Disturbances In Patients With Dementia With Lewy Bodies

Today's Vidyya articles are:

As always, we hope you enjoy the issue.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.